Abstract：Objective To study the clinical efficacy of valsartan(Val) combined with amlodipine(Aml) for elderly hypertensive patients above 65.Methods 165 patients above 65 with primary hypertension were treateded in our hospital between January 2014 and January 2015. They were randomly divided into group A (valsartan), B (amlodipine), C (combination therapy group) according to the random number table. Patients in each group were treated wtih Val, Aml and Val+Aml for 1 year. The 24-hour mean blood pressure and adverse reactions of the three groups were observed.Results Systolic and diastolic pressure of group A, B and C after 24 hours of treatment decreased significantly(P<0.05), while the antihypertensive effect was not significantly different between group A and group B (P＞0.05).Blood pressure decreased more significantly in group C than in group A and B(P<0.05). The total effective rate of group C was significantly higher than that of group A and B(P<0.05). The incidence of adverse events was not significantly different between the three groups(P>0.05).Conclusions Valsartan combined with amlodipine has better clinical efficacy for hypertensive patients above65 and is worthy of clinical application.
Sison J, Assaadkhalil S H, Najem R, et al. Real-world clinical experience of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in hypertension: the EXCITE study[J]. Curr Med Res Opin, 2014, 30(10):1937-1945.
[2]
Shin S, Song H, Oh S K, et al. Effect of antihypertensive medication adherence on hospitalization for cardiovascular disease and mortality in hypertensive patients [J]. Hypertens Res,2013, 36(11):1000-1005.
[3]
Thom S, Poulter N, Field J, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial [J]. JAMA,2013, 310(9):918-929.
[4]
Zhu D, Yang K, Sun N, et al. Amlodipine/valsartan 5/160mg versus valsartan 160mg in Chinese hypertensives [J]. Int J Cardiol,2013,167(5):2024-2030.
[5]
Ogawa H, Kim-Mitsuyama S, Matsui K, et al. Angiotensin II Receptor Blocker-based Therapy in Japanese Elderly, High-risk, Hypertensive Patients[J]. Am J Med, 2012, 125(10):981-990.
[6]
Chow C K, Teo K K, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries [J]. JAMA, 2013, 310(9):959-968.
[7]
Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) [J]. European Heart Journal,2013,34(28):3-16.
[8]
Ogihara T, Saruta T, Rakugi H, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study [J]. Hypertension, 2010, 56(2):196-202.
[9]
Kidambi S, Kotchen T A. Treatment of Hypertension in Obese Patients[J]. American Journal of Cardiovascular Drugs, 2013, 9(397):1624-1626.
[10]
Mallat S G, Itani H S, Tanios B Y. Current perspectives on combination therapy in the management of hypertension[J]. Integr Blood Press Control, 2013, 6:69-78.
[11]
Hu D, Liu L, Li W. Efficacy and Safety of Valsartan/Amlodipine Single-Pill Combination in 11,422 Chinese Patients with Hypertension: an Observational Study[J]. Adv Ther,2014, 31(7):762-775.
2016, Vol. 27 
